Patents by Inventor Stefano Zanotti

Stefano Zanotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
    Publication number: 20240117356
    Abstract: The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 11, 2024
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Timothy Weeden, Cody A. Waltham, Stefano Zanotti, Kim Tang, Mohammed T. Qatanani, Brendan Quinn, John Najim
  • Muscle targeting complexes and formulations for treating myotonic dystrophy
    Patent number: 11931421
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: March 19, 2024
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Scott Hilderbrand, Timothy Weeden, John Najim, Stefano Zanotti, Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Kim Tang, Brendan Quinn
  • MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY
    Publication number: 20230330247
    Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).
    Type: Application
    Filed: April 19, 2023
    Publication date: October 19, 2023
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Scott Hilderbrand, Timothy Weeden, John Najim, Stefano Zanotti, Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Kim Tang, Brendan Quinn